Our management believes that our existing capital resources, including the net proceeds of this offering, in combination with the net proceeds from our financing activities in April 2005 and $29.625 million available for borrowing under our third-lien term loan and up to an additional $25.0 million under our revolving credit facility will be sufficient to maintain and grow our current operations. Our longer-term liquidity and capital requirements will depend upon numerous factors including our operating performance, significant economic, regulatory, product supply and competitive uncertainties in addition to the cost to license or acquire new products or product development candidates, the expansion of our sales force and related infrastructure and the conduct of clinical trials in support of development projects. If required, we may raise such additional funds through public or private debt or equity financings or other arrangements. There can be no assurance that such financing will be available on terms acceptable to us, if at all, or that such financing will not be dilutive to our stockholders.

Summary of Cash Flows